Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

NCT05616923 is registered in ClinicalTrials.gov with Albany Research Institute, Inc. as lead sponsor.

NCT NCT05616923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05616923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
Lead sponsor
Albany Research Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2021
Completion date
December 31, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea, erythematotelangiectatic